Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 31.0 kDa.
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
5e5 of anti-CD7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HP2H6) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
5e5 of PBMCs were stained with PE-Labeled Human CD7 Protein, His Tag (Cat. No. CD7-HP2H6) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
GC-027 | GC-027 | Phase 1 Clinical | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD7 CAR-T cell Therapy (Shanghai General Hospital) | Phase 1 Clinical | Shanghai General Hospital | Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell | Details | |
PA3-17 | PA3-17; PA-3-17; PA3-17 (autologous) | Phase 1 Clinical | Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
SenL-T7 CAR T Cells (Hebei Senlang Biological) | Senl-T7; Senl-T-7; SENL-101 | Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This CAR-T-7 cells therapy | This CAR-T-7 cells | Fundamenta Therapeutics Ltd | Details | ||
GC-502 | GC-502 | Details | |||
Anti-CD7 universal CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Xinqiao Hospital, Army Medical University | Lymphoma, T-Cell; Leukemia, T-Cell | Details | |
CD7-CAR-T cell therapy (PersonGen Biomedicine) | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University | Leukemia; Enteropathy-Associated T-Cell Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic | Details | |
CAR7-T Cell Therapy (Beijing Gaobo Biotechnology Co Ltd) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, T-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Humanized CD7 CAR-T cells | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma, T-Cell | Details | |
CD7 CAR-T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD7 CAR T-cell therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Still's Disease, Adult-Onset; Leukemia; Dermatomyositis; Autoimmune Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Colitis, Ulcerative; Lymphoma; Crohn Disease | Details | |
Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics) | BT-007 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, Bioceltech Therapeutics Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
WU-CART-007 | WU-CART-007 | Phase 2 Clinical | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Leukemia-Lymphoma, Adult T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Mycosis Fungoides | Details | |
CD7 CARvac T cell therapy | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
CD7 targeted CAR-γδ T cells therapy(Persongen Bio) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Neoplasms; Leukemia, B-Cell | Details | |
RD13-01 | RD13-01; CTD-401 | Clinical | Zhejiang University, Nanjing Bioheng Biotech Co Ltd | Hematologic Neoplasms | Details |
Anti-CD3 ricin chain A conjugate/anti-CD7 ricin chain A conjugate | HENO-3; SPV-T3a | Phase 3 Clinical | Xenikos Bv | Graft vs Host Disease | Details |
BEAM-201 | BEAM-201 | Phase 1 Clinical | Beam Therapeutics Inc | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
This web search service is supported by Google Inc.